BluEnergies Ltd. (BLUGF)
| Market Cap | 137.04M +168.0% |
| Revenue (ttm) | n/a |
| Net Income | -4.66M |
| EPS | -0.15 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,400 |
| Open | 1.700 |
| Previous Close | 1.640 |
| Day's Range | 1.687 - 1.740 |
| 52-Week Range | 1.128 - 2.680 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 25, 2026 |
About BluEnergies
BluEnergies Ltd. operates as an oil and gas exploration and development company in the Republic of Liberia. It holds 100% interest in Blocks LB-26, LB-30, and LB-31 covering an area of approximately 8,924 square kilometers located in the Harper basin, offshore Liberia. BluEnergies Ltd. is headquartered in Vancouver, Canada. [Read more]
News
BLUENERGIES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF C$20.7 MILLION
VANCOUVER, BC, July 23, 2026 /PRNewswire/ - BluEnergies Ltd. (TSXV: BLU) (OTCQX: BLUGF) (F: 66E) ("BLU" or the "Company") is pleased to announce that, further to its news releases dated July 9, 2026 a...
BLUENERGIES ANNOUNCES DTC ELIGIBILITY, ENGAGEMENT OF MARKET MAKER AND INITIATION OF RESEARCH COVERAGE
TSXV: BLU | OTCQX: BLUGF VANCOUVER, BC, April 27, 2026 /PRNewswire/ - BluEnergies Ltd. (TSXV: BLU) ("BLU" or the "Company") is pleased to announce that its common shares are now eligible for electroni...
GSK says Bellus deal to be adjusted earnings accretive from 2027
GSK (GSK) and Bellus Health (BLU) announced GSK has completed the acquisition of Bellus. Following the anticipated regulatory approval and launch of camlipixant, the acquisition is expected to be accr...
Bellus Health downgraded to Hold from Buy at Jefferies
Jefferies downgraded Bellus Health (BLU) to Hold from Buy with a price target of $14.75, down from $21, after GSK (GSK) announced its agreement to acquire Bellus for $2B in…
Bellus Health cut to Sector Perform at RBC Capital on GSK deal
RBC Capital downgraded Bellus Health (BLU) to Sector Perform from Outperform with a price target of $14.75, down from $21 after the company reached an agreement to be acquired by…
Bellus Health downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Bellus Health (BLU) to In Line from Outperform with a price target of $14.75, down from $24, after the company agreed to a deal to be acquired…
GSK to acquire Bellus Health for $14.75 per share
GSK plc (GSK) and Bellus Health (BLU) announced that they have entered into an agreement under which GSK will acquire Bellus, a Canada-based, late-stage biopharmaceutical company working to better the...
BELLUS Health: Drug Trial Results SOOTHE the Market
BELLUS Health (BLU) is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (RCC) and other hypersensitization-related disorders. The ...